Aeglea Bio Therapeutics Inc
Change company Symbol lookup
Select an option...
AGLE Aeglea Bio Therapeutics Inc
BLUE bluebird bio Inc
ENSV Enservco Corp
ULIHF United Laboratories International Holdings Ltd
ABOIF Aboitiz Equity Ventures Inc
VYNE Vyne Therapeutics Inc
CEAD CEA Industries Inc
BFRI Biofrontera Inc
ARW Arrow Electronics Inc
SF-B Stifel Financial Corp
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. It is focused on human enzyme therapeutics to treat people with rare metabolic diseases. Its lead product candidate is pegzilarginase, which is a recombinant human arginase 1 that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase 1 Deficiency. It has engineered pegzilarginase with modifications that enhance the stability and arginine-degrading activity of the enzyme in human plasma. Its second product candidate, AGLE-177, is a novel PEGylated ( polyethylene glycol) human enzyme engineered to degrade free homocysteine and homocystine in patients with Homocystinuria. The Company is evaluating Pegzilarginase in a global pivotal Phase III pivotal PEACE (Pegzilarginase Effect on Arginase one Deficiency Clinical Endpoints) trial and Phase I/II open-label extension trial. It is also conducting a Phase I/II clinical trial for the treatment of patients with Homocystinuria.

Price
Delayed
$0.4964
Day's Change
-0.0137 (-2.68%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.549
Day's Low
0.4933
Volume
(Light)

Today's volume of 117,040 shares is on pace to be much lighter than AGLE's 10-day average volume of 843,322 shares.

117,040
Latest Earnings Missed Consensus (Q1 ending 03/2022)Next Earnings Announcement
Q1
Announced May 5, 2022
-$0.37Q1 Consensus
of 6 analysts
-$0.34Difference from
consensus
-9.79%
Q2 Earnings
will announce
(Unconfirmed) August 3, 2022

Quarterly Earnings History and Estimates

Show high-low estimates
Draw trendlines

Draw up to 3 lines inside the chart.

Display:

UpdateCancel

AGLE's fiscal year ends in December

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.